ETFMG Treatments, Testing and Advancements ETF (GERM)
| 36.99 BATS BZX Real-Time Price As of 2:36pm ET |  +0.59 / +1.62%Today’s Change | 23.80 Today|||52-Week Range 44.69 | +18.94% Year-to-Date |
Investment Objective
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the Prime Treatments, Testing and Advancements Index. The index tracks the performance of U.S.-listed equity securities or depositary receipts of companies that (i) perform research, development, and commercialization of treatments or vaccines for infectious diseases or (ii) engage in the research, development, manufacturing, and provision of biological tests for patients. The fund invests at least 80% of its total assets in the component securities of the index. The fund is non-diversified.
Latest GERM News
No recent news for ETFMG Treatments, Testing and Advancements ETF.
Performance
| 1 month | -0.23% | 3 years | -- | |
| 3 months | +1.68% | 5 years | -- | |
| 1 year | -- | Since inception | +46.43% |
Data through 04/15/2021
Quote Details
| Previous close | $36.40 |
| Open day’s range | 36.55 – 36.99 |
| Net asset value (NAV) | 36.31 (04/14/2021) |
| Daily volume | 18,815 |
| Average volume (3 months) | 31,707 |
Data as of 2:36pm ET, 04/16/2021
Peer Comparisonvs. Health ETFs
| GERM | Category | |
|---|---|---|
| Performance 5-yr return | -- | +15.28% |
| Expense Gross exp ratio | 0.68% | 1.02% |
| Risk 5 year sharpe ratio | -- | 0.80 |
| Net assets | $56.7M | $2.3B |
| Average market cap | $10.7B | $31.0B |
| Average P/E | -- | 28.0 |
| Dividend / Share | -- | 0.29% |
Competitors
| No competitors data available. |
Holdings
Top 5 SectorsPortfolio weighting
| Business service | -- |
| Consumer goods | -- |
| Consumer service | -- |
| Energy | -- |
| Financial service | -- |
Top 10 HoldingsPortfolio weighting
| BNTX BioNTech SE | 6.47% |
| LH Laboratory Corporation of America Holdings | 6.11% |
| ALNY Alnylam Pharmaceuticals Inc | 5.79% |
| BIO Bio Rad Laboratories Inc | 5.72% |
| MRNA Moderna Inc | 5.58% |
| NVAX Novavax Inc | 4.30% |
| ABCL Abcellera Biologics Inc | 4.26% |
| -- | 4.22% |
| DGX Quest Diagnostics Inc | 4.10% |
| ZLAB Zai Lab Ltd | 3.76% |
